Heart Valve Market By Product Type (Mechanical Heart Valves; Transcatheter Heart Valves; Bioprosthetic Heart Valves); By Valve Type (Aortic Valve; Mitral Valve; Pulmonary Valve; Tricuspid Valve); By Procedure Type (Surgical Valve Replacement; Transcatheter Valve Replacement; Surgical Valve Repair; Transcatheter Valve Repair); By End-User (Hospitals; Ambulatory Surgical Centers (ASCs); Specialty Cardiac Centers); By Geography, Segment Revenue Estimation, Forecast, 2024–2032.

Heart Valve Market Size & Overview

The heart valve market was valued at approximately $9.8 billion in 2024 and is projected to reach $18.6 billion by 2030, expanding at a CAGR of 11.3% during the forecast period. The market is driven by the rising prevalence of valvular heart diseases, particularly among the aging population, and the increasing adoption of minimally invasive procedures such as transcatheter aortic valve replacement (TAVR) & transcatheter mitral valve repair (TMVR).

 

Technological advancements, including next-generation bioprosthetic valves, polymeric valves & AI-driven imaging solutions, are enhancing procedural success rates and expanding treatment options. North America currently holds the largest market share due to strong healthcare infrastructure, high adoption of advanced cardiac devices, and a growing patient pool with cardiovascular conditions. The transcatheter heart valves segment leads the market, driven by increasing preference over traditional surgical valve replacement. However, high procedural costs, stringent regulatory approvals & risks associated with valve implantation remain key challenges. Despite these barriers, continued R&D investments, strategic collaborations & geographical expansion by major players are expected to propel market growth in the coming years.

 

Heart Valve Market Dynamics:

Market Drivers

Rising Prevalence of Cardiovascular Diseases (CVDs)

The increasing incidence of cardiovascular diseases, including valvular heart diseases, is a significant driver of the heart valve market. For decades, cardiovascular diseases (CVDs) have remained the leading cause of death worldwide. In 2021, approximately 20.5 million people died due to cardiovascular conditions, accounting for around one-third of all global deaths. According to the WHO, CVDs account for nearly 17.9 million deaths annually, making it the leading cause of death worldwide. Ischemic heart disease has now become the primary cause of premature death in 146 countries for men & 98 countries for women. The aging population, sedentary lifestyles & rising prevalence of risk factors such as diabetes & hypertension are further contributing to the increased demand for heart valve replacements & repairs. The demand for TAVR procedures has surged in recent years, especially for elderly patients who are at high risk for open-heart surgery.

Advancements in Heart Valve Technology

The latest advancements in heart valve replacement, from TAVR to bioengineered valves, are reshaping cardiovascular medicine. These innovations improve survival rates and enhance the quality of life for individuals globally. One of the significant breakthroughs in heart valve replacement is Transcatheter Aortic Valve Replacement (TAVR). Currently TAVR is the choice for people above the age of 80. According to a report by the American College of Cardiology, over 100,000 TAVR procedures are performed annually in the U.S., indicating a shift towards less invasive treatment options. The adoption of advanced materials, such as polymeric heart valves & next-generation bioprosthetic valves, has also enhanced patient outcomes & durability. Abbott's MitraClip has revolutionized the mitral valve repair landscape by offering a catheter-based alternative for patients with mitral regurgitation who are not candidates for open-heart surgery.

 

Market Opportunities

Growing Adoption of Transcatheter Heart Valves in Emerging Markets

In the last fourteen years, TAVR has been performed in around 300,000 patients in 65 countries & adoption is increasing by 40% year on year. In the US, the number of Transcatheter Aortic Valve Replacements (TAVRs) exceeded all Surgical Aortic Valve Replacements (SAVRs) in 2019, with 72,991 cases compared to 57,626 cases, respectively. This represents a 15-fold increase from the 4,666 TAVR cases performed in 2012, alongside an 8% decrease in all SAVRs during the same period. Emerging economies, particularly in APAC & Latin America, present significant growth opportunities due to improving healthcare infrastructure & rising awareness about heart valve diseases.

Integration of Artificial Intelligence (AI) & 3D Printing in Valve Manufacturing

Artificial intelligence (AI) & machine learning are playing a crucial role in refining the design & functionality of 3D-printed heart valves. By analyzing vast datasets of patient scans & surgical outcomes, AI algorithms can generate optimized valve designs that maximize durability & performance. AI helps in precise diagnosis & patient selection, while 3D printing enables the customization of heart valves tailored to individual patient anatomy, improving procedural success rates. Researchers from the Technical University of Munich & The University of Western Australia have successfully replicated the heterogeneous structure of heart valve tissue using a 3D printing process called melt electrowriting. This innovative platform allows for the precise customization of patterns and the fine-tuning of mechanical properties within the same scaffold. This breakthrough in heart valve technology has the potential to significantly impact the cardiovascular market. Companies like Boston Scientific are leveraging AI-based imaging software to enhance preoperative planning, ensuring better outcomes in TAVR & surgical valve replacement procedures.

 

Market Challenges

High Cost of Heart Valve Procedures & Devices

Although heart valve technology has improved, the high cost of valve replacement procedures remains a major obstacle, especially in developing regions. A single Transcatheter Aortic Valve Replacement (TAVR) procedure can cost between $30,000 - $50,000, making it too expensive for many patients without proper insurance coverage. In many countries, access to advanced heart valve treatments is restricted due to financial limitations. As a result, patients often choose traditional open-heart surgeries, which are relatively more affordable but require longer recovery times.

Regulatory Challenges & Product Recalls

Strict regulatory approval processes & frequent product recalls can slow down market growth. Heart valves must undergo extensive clinical trials & obtain regulatory approvals, which can delay the introduction of new products. Recalls due to device failures or safety issues can harm the credibility of manufacturers & erode patient confidence. In 2021, Medtronic recalled its HeartWare HVAD system over concerns about its safety & performance, illustrating the challenges manufacturers face in ensuring long-term device reliability.

 

Heart Valve Market Segmentation: A Comprehensive Overview

By Product Type:

• Mechanical Heart Valves

• Transcatheter Heart Valves

• Bioprosthetic Heart Valves

 

By Valve Type:

• Aortic Valve

• Mitral Valve

• Pulmonary Valve

• Tricuspid Valve

 

By Procedure Type:

• Surgical Valve Replacement

• Transcatheter Valve Replacement

• Surgical Valve Repair

• Transcatheter Valve Repair

 

By End-User:

• Hospitals

• Ambulatory Surgical Centers (ASCs)

• Specialty Cardiac Centers

 

By Region:

• North America

• Europe

• Asia-Pacific

• Latin America

• Middle East & Africa

 

Heart Valve Market Segment Analysis: Growth Trends Across Categories

By Product Type:

Leading Segment: Bioprosthetic Heart Valves

Bioprosthetic heart valves hold the largest market share in the global heart valve market. These valves, made from biological tissues, are preferred for their compatibility & lower risk of thrombosis compared to mechanical valves. The demand for bioprosthetic valves is especially high in elderly patients due to their reduced need for lifelong anticoagulation therapy. This segment accounts for approximately 40% of the total market share. With the increasing aging population & advancements in tissue-engineering technologies, the bioprosthetic segment is expected to continue its dominance in the coming years.

Fastest-Growing Segment: Transcatheter Heart Valves

Transcatheter heart valves represent the fastest-growing segment of the heart valve market. These valves are gaining significant traction due to their minimally invasive procedure & shorter recovery times compared to traditional surgical valve replacement. The segment is projected to expand at a CAGR of 14% over the next five years, driven by the increasing adoption of transcatheter aortic valve replacement (TAVR) procedures, particularly in patients who are high-risk or inoperable for open-heart surgery. The demand is further bolstered by improvements in device design and clinical outcomes.

 

By Valve Type:

Leading Segment: Aortic Valve

The aortic valve segment leads the heart valve market, primarily due to the high incidence of aortic valve diseases, such as aortic stenosis, which require surgical intervention. It is estimated that the aortic valve segment constitutes 50% of the total heart valve market share. The increasing prevalence of aortic valve diseases, especially among the aging population & the introduction of innovative valve replacement procedures (like TAVR) contribute to the aortic valve's dominance.

Fastest-Growing Segment: Mitral Valve

The mitral valve segment is the fastest-growing segment in the heart valve market, with a CAGR of 10%. People are increasingly noticing problems with the mitral valve, like mitral regurgitation & mitral stenosis. There's also a growing preference for less invasive surgical procedures. These factors are driving the market's growth. New advancements in transcatheter mitral valve repair (TMVR) & replacement procedures are expected to further boost the market's expansion in this area.

 

By Procedure Type:

Leading Segment: Surgical Valve Replacement

Surgical valve replacement remains the leading procedure type in the heart valve market, making up a significant portion of the market share. This procedure is especially common for patients with severe valve conditions. Surgical valve replacement accounts for approximately 55% of the total market share. Despite the growing adoption of transcatheter procedures, traditional surgical valve replacement continues to be favored for younger patients and those requiring long-term solutions, particularly in the aortic and mitral valve segments.

Fastest-Growing Segment: Transcatheter Valve Replacement

Transcatheter valve replacement (TVR) is the fastest-growing procedure type in the heart valve market, with a CAGR of 18%. The significant growth of this segment can be attributed to the increasing preference for minimally invasive procedures, which offer lower risk, faster recovery times, and fewer complications compared to traditional surgeries. TAVR, in particular, is driving growth in the aortic valve replacement market, with expanded indications & clinical guidelines encouraging its use for intermediate-risk patients as well.

 

By End-User:

Leading Segment: Hospitals

Hospitals dominate the heart valve market as the primary end-user for heart valve surgeries and procedures. Hospitals account for approximately 65% of the total market share, as they are the main centers for complex cardiac surgeries and interventions. The availability of advanced infrastructure, skilled cardiothoracic surgeons, and post-operative care makes hospitals the preferred setting for heart valve replacement and repair surgeries.

Fastest-Growing Segment: Ambulatory Surgical Centers (ASCs)

Ambulatory surgical centers (ASCs) are the fastest-growing end-user segment in the heart valve market, with a CAGR of 12%. The growth of ASCs is driven by the increasing adoption of minimally invasive transcatheter valve replacement procedures and the growing preference for outpatient procedures, which require shorter recovery times and lower costs. ASCs are becoming more popular as they offer specialized heart valve procedures in a cost-effective & convenient setting, especially for less complex cases.

 

By Region:

Leading Region: North America

North America holds the largest market share in the global heart valve market, with the United States being the largest contributor. The North American market accounts for approximately 40% of the global market share. This dominance is driven by the high incidence of heart valve diseases, advanced healthcare infrastructure, and high adoption rates of both surgical and transcatheter heart valve replacement procedures. The presence of leading heart valve manufacturers & the growing elderly population in the region further contribute to its dominance.

Fastest-Growing Region: Asia-Pacific

The APAC region is the fastest-growing region for the heart valve market, with a CAGR of 11%. The increasing prevalence of heart valve diseases, particularly in countries like China & India, combined with the growing healthcare infrastructure, is driving the demand for heart valve treatments in this region. The rise in disposable income, increasing healthcare awareness & improving access to advanced medical technologies are all contributing to the rapid growth in the Asia-Pacific heart valve market.

 

Key Players in the Heart Valve Market

• Edwards Lifesciences Corporation

• Medtronic plc

• Abbott Laboratories

• Boston Scientific Corporation

• LivaNova PLC

• CryoLife, Inc.

• Artivion, Inc. (formerly CryoLife)

• Braile Biomédica

• Colibri Heart Valve LLC

• Micro Interventional Devices, Inc.

 

Heart Valve Market Report Coverage

Report Attribute	Details
Forecast Period	2024 – 2032
Market Size Value in 2024	USD 9.8 Billion
Revenue Forecast in 2030	USD 18.6 Billion
Overall Growth Rate	CAGR of 11.3% (2024 – 2030)
Base Year for Estimation	2023
Historical Data	2017 – 2021
Unit	USD Million, CAGR (2024 – 2032)
Segmentation	By Product Type, By Valve Type, By Procedure Type, By End User, By Geography
By Product Type	Mechanical Heart Valves; Transcatheter Heart Valves; Bioprosthetic Heart Valves
By Valve Type	Aortic Valve; Mitral Valve; Pulmonary Valve; Tricuspid Valve
By Procedure Type	Surgical Valve Replacement; Transcatheter Valve Replacement; Surgical Valve Repair; Transcatheter Valve Repair
By End User	Hospitals; Ambulatory Surgical Centers (ASCs); Specialty Cardiac Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	US, Canada, Germany, China, India, etc.
Market Drivers	Rising prevalence of valvular heart diseases, increasing adoption of transcatheter heart valves, technological advancements in heart valve therapies
Pricing and Purchase Options	Customized options available

 

Recent Developments

• Acquisitions to Expand Structural Heart Portfolio (July 2024): Edwards announced plans to acquire Innovalve Bio Medical for approximately $300 million and JenaValve Technology and Endotronix for $1.2 billion, aiming to enhance its offerings in mitral and tricuspid valve therapies.

• Launch of Evolut FX TAVR System (2023): Medtronic introduced the Evolut FX Transcatheter Aortic Valve Replacement system, featuring design enhancements for improved valve performance and ease of use during implantation.

• Acquisition of Tendyne Holdings (2022): Abbott expanded its structural heart portfolio by acquiring Tendyne Holdings, a company specializing in minimally invasive mitral valve replacement technologies

 

Future Outlook

The global heart valve market is poised for significant growth, driven by technological advancements, the rising prevalence of valvular heart diseases, and increasing adoption of minimally invasive procedures like transcatheter aortic valve replacement (TAVR). The growing geriatric population, coupled with higher awareness & improved access to healthcare in emerging markets, is expected to fuel demand. Innovations such as AI-powered imaging, 3D-printed valves & next-generation bioprosthetic valves will enhance precision & durability, improving patient outcomes. However, challenges like high costs, stringent regulatory approvals & limited reimbursement policies in some regions may slow adoption. Leading manufacturers are actively investing in research & development, strategic acquisitions & geographical expansion to strengthen their market position. As AI-driven diagnostics & patient-specific valve solutions become mainstream, the market is expected to witness a shift toward personalized treatment approaches, ultimately improving long-term survival rates & quality of life for patients worldwide.